Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8844465 | 0.84 | PDCD1LG2 (0.52) | PDCD1LG2CD274USP30SIGMAR1DRD2 | |
| SCHEMBL14868702 | 0.84 | PDCD1LG2 (0.52) | PDCD1LG2CD274USP30SIGMAR1DRD2 | |
| SCHEMBL8844573 | 0.79 | TP53 (0.59) | PDCD1LG2CD274SIGMAR1ROCK2DRD2 | |
| SCHEMBL1740324 | 0.78 | CYP2D6 (0.52) | USP30SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL19116698 | 0.78 | CD274 (0.47) | PDCD1LG2CD274 | |
| SCHEMBL2636322 | 0.78 | BCHE (0.53) | USP30DRD2DRD4DRD3ACHE | |
| SCHEMBL1546893 | 0.77 | USP30 (0.48) | USP30SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL8844231 | 0.77 | TRPV6 (0.57) | SIGMAR1DRD2CCR5CXCR4ACHE | |
| SCHEMBL6195713 | 0.77 | DRD4 (0.59) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL13887159 | 0.76 | FFAR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7652134-B2 | Tumor suppression agents with reduced side effects; anticancer; antibacterial and antiviral; contacting the corresponding ester with an amine and a Lewis acid | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652134-B2 | Tumor suppression agents with reduced side effects; anticancer; antibacterial and antiviral; contacting the corresponding ester with an amine and a Lewis acid | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | PDCD1LG2 4378/4885CD274 3921/4885USP30 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.